Compare CMMB & MRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMMB | MRM |
|---|---|---|
| Founded | 2004 | 2000 |
| Country | Israel | Japan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 10.0M |
| IPO Year | 2023 | 2020 |
| Metric | CMMB | MRM |
|---|---|---|
| Price | $1.85 | $1.26 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $25.00 | N/A |
| AVG Volume (30 Days) | 69.1K | ★ 174.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.67 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $48.75 | ★ $32.01 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $0.34 |
| 52 Week High | $3.86 | $4.45 |
| Indicator | CMMB | MRM |
|---|---|---|
| Relative Strength Index (RSI) | 53.82 | 35.54 |
| Support Level | $1.57 | $1.16 |
| Resistance Level | $2.80 | $1.64 |
| Average True Range (ATR) | 0.19 | 0.10 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 62.51 | 23.91 |
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.